Galectin Therapeutics Appoints Henry Brem, NIH-Funded Neurosurgeon with 416 Publications
Galectin Therapeutics has appointed Henry Brem, M.D., a neurosurgeon-scientist and Henry Brem Professor of Neurosurgery at Johns Hopkins, to its board as an independent director. Brem’s four-decade NIH-funded research, 416 peer-reviewed papers and experience advancing Gliadel® wafers support Galectin’s belapectin clinical development in MASH cirrhosis and portal hypertension.
1. Board Appointment of Henry Brem
Galectin Therapeutics has appointed Henry Brem, M.D., as an independent director to its Board. Brem serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.
2. Extensive Scientific and Clinical Achievements
Brem is an internationally recognized neurosurgeon-scientist with over four decades of continuous NIH funding, 416 peer-reviewed papers, multiple patents and membership in the National Academy of Medicine, highlighting his translational research leadership.
3. Strategic Support for Belapectin Development
Brem’s experience developing image-guided techniques and Gliadel® wafers for brain tumors will bolster Galectin’s belapectin clinical programs in MASH cirrhosis and portal hypertension as the company advances toward regulatory milestones.